OCM
KPTI icon

Opti Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

Opti Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-8,333
Closed -$84.5K – 54
2024
Q4 		$84.5K Buy
+8,333
New +$101K ﹤0.01% 66

Other funds holding KPTI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Opti Capital Management's KPTI Position: Q1 2025 in Review

Opti Capital Management sold out of Karyopharm Therapeutics (KPTI) in Q1 2025, closing a stake of 8,333 shares — an estimated $84.5K sold.

Opti Capital Management first reported a position in KPTI in Q4 2024 and held it in 1 quarter. The position peaked at $84.5K in Q4 2024. 49 funds tracked by Wall St. Rank hold KPTI as of Q1 2025.

  • Opti Capital Management reported no remaining Karyopharm Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Opti Capital Management sold 8,333 Karyopharm Therapeutics shares in Q1 2025, an estimated $84.5K.
  • Opti Capital Management first reported a position in Karyopharm Therapeutics in Q4 2024 and held it in 1 quarter.
  • Opti Capital Management's Karyopharm Therapeutics position peaked at $84.5K in Q4 2024.
  • 49 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2025.

Based on Opti Capital Management's 13F filing for Q1 2025, filed 15 May 2025.